Literature DB >> 29030465

Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.

Paraskevas Iatropoulos1, Erica Daina2, Manuela Curreri1, Rossella Piras1, Elisabetta Valoti1, Caterina Mele1, Elena Bresin1, Sara Gamba1, Marta Alberti1, Matteo Breno1, Annalisa Perna1, Serena Bettoni1, Ettore Sabadini3, Luisa Murer4, Marina Vivarelli5, Marina Noris1, Giuseppe Remuzzi1,3,6.   

Abstract

Membranoproliferative GN (MPGN) was recently reclassified as alternative pathway complement-mediated C3 glomerulopathy (C3G) and immune complex-mediated membranoproliferative GN (IC-MPGN). However, genetic and acquired alternative pathway abnormalities are also observed in IC-MPGN. Here, we explored the presence of distinct disease entities characterized by specific pathophysiologic mechanisms. We performed unsupervised hierarchical clustering, a data-driven statistical approach, on histologic, genetic, and clinical data and data regarding serum/plasma complement parameters from 173 patients with C3G/IC-MPGN. This approach divided patients into four clusters, indicating the existence of four different pathogenetic patterns. Specifically, this analysis separated patients with fluid-phase complement activation (clusters 1-3) who had low serum C3 levels and a high prevalence of genetic and acquired alternative pathway abnormalities from patients with solid-phase complement activation (cluster 4) who had normal or mildly altered serum C3, late disease onset, and poor renal survival. In patients with fluid-phase complement activation, those in clusters 1 and 2 had massive activation of the alternative pathway, including activation of the terminal pathway, and the highest prevalence of subendothelial deposits, but those in cluster 2 had additional activation of the classic pathway and the highest prevalence of nephrotic syndrome at disease onset. Patients in cluster 3 had prevalent activation of C3 convertase and highly electron-dense intramembranous deposits. In addition, we provide a simple algorithm to assign patients with C3G/IC-MPGN to specific clusters. These distinct clusters may facilitate clarification of disease etiology, improve risk assessment for ESRD, and pave the way for personalized treatment.
Copyright © 2018 by the American Society of Nephrology.

Entities:  

Keywords:  C3 glomerulonephritis; C3 glomerulopathy; Complement system; Dense Deposit Disease; Rare diseases; membranoproliferative glomerulonephritis (MPGN)

Mesh:

Substances:

Year:  2017        PMID: 29030465      PMCID: PMC5748907          DOI: 10.1681/ASN.2017030258

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  32 in total

Review 1.  The identification of Parkinson's disease subtypes using cluster analysis: a systematic review.

Authors:  Stephanie M van Rooden; Willem J Heiser; Joost N Kok; Dagmar Verbaan; Jacobus J van Hilten; Johan Marinus
Journal:  Mov Disord       Date:  2010-06-15       Impact factor: 10.338

2.  Eculizumab for dense deposit disease and C3 glomerulonephritis.

Authors:  Andrew S Bomback; Richard J Smith; Gaetano R Barile; Yuzhou Zhang; Eliot C Heher; Leal Herlitz; M Barry Stokes; Glen S Markowitz; Vivette D D'Agati; Pietro A Canetta; Jai Radhakrishnan; Gerald B Appel
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-08       Impact factor: 8.237

3.  C3 deposition glomerulopathy due to a functional factor H defect.

Authors:  Sandra Habbig; Michael J Mihatsch; Stefan Heinen; Bodo Beck; Mathias Emmel; Christine Skerka; Michael Kirschfink; Bernd Hoppe; Peter F Zipfel; Christoph Licht
Journal:  Kidney Int       Date:  2008-07-16       Impact factor: 10.612

4.  Toward a working definition of C3 glomerulopathy by immunofluorescence.

Authors:  Jean Hou; Glen S Markowitz; Andrew S Bomback; Gerald B Appel; Leal C Herlitz; M Barry Stokes; Vivette D D'Agati
Journal:  Kidney Int       Date:  2013-09-25       Impact factor: 10.612

5.  C3 glomerulopathy: clinicopathologic features and predictors of outcome.

Authors:  Nicholas R Medjeral-Thomas; Michelle M O'Shaughnessy; John A O'Regan; Carol Traynor; Michael Flanagan; Limy Wong; Chia Wei Teoh; Atif Awan; Mary Waldron; Tom Cairns; Patrick O'Kelly; Anthony M Dorman; Matthew C Pickering; Peter J Conlon; H Terence Cook
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-31       Impact factor: 8.237

6.  Heterogeneous histologic and clinical evolution in 3 cases of dense deposit disease with long-term follow-up.

Authors:  Marie-Lucile Figuères; Véronique Frémeaux-Bacchi; Marion Rabant; Louise Galmiche; Maria Chiara Marinozzi; Jean-Pierre Grünfeld; Laure-Hélène Noël; Aude Servais
Journal:  Hum Pathol       Date:  2014-08-16       Impact factor: 3.466

Review 7.  Pathogenesis of the C3 glomerulopathies and reclassification of MPGN.

Authors:  Andrew S Bomback; Gerald B Appel
Journal:  Nat Rev Nephrol       Date:  2012-10-02       Impact factor: 28.314

8.  Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II).

Authors:  C Licht; S Heinen; M Józsi; I Löschmann; R E Saunders; S J Perkins; R Waldherr; C Skerka; M Kirschfink; B Hoppe; P F Zipfel
Journal:  Kidney Int       Date:  2006-04-12       Impact factor: 10.612

9.  Long-term prognosis of membranoproliferative glomerulonephritis type I. Significance of clinical and morphological parameters: an investigation of 220 cases.

Authors:  H Schmitt; A Bohle; T Reineke; D Mayer-Eichberger; W Vogl
Journal:  Nephron       Date:  1990       Impact factor: 2.847

10.  Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.

Authors:  Paraskevas Iatropoulos; Marina Noris; Caterina Mele; Rossella Piras; Elisabetta Valoti; Elena Bresin; Manuela Curreri; Elena Mondo; Anna Zito; Sara Gamba; Serena Bettoni; Luisa Murer; Veronique Fremeaux-Bacchi; Marina Vivarelli; Francesco Emma; Erica Daina; Giuseppe Remuzzi
Journal:  Mol Immunol       Date:  2016-02-16       Impact factor: 4.407

View more
  32 in total

1.  Characteristics of membranoproliferative glomerulonephritis based on a new classification at a single center.

Authors:  Marie Nakano; Kazunori Karasawa; Takahito Moriyama; Keiko Uchida; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2019-03-11       Impact factor: 2.801

2.  Nephro Update Europe 2018.

Authors:  Nina Kesel
Journal:  Kidney Dis (Basel)       Date:  2019-04-26

Review 3.  Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.

Authors:  Marina Noris; Roberta Donadelli; Giuseppe Remuzzi
Journal:  Pediatr Nephrol       Date:  2018-06-09       Impact factor: 3.714

4.  Challenges in Understanding Acute Postinfectious Glomerulonephritis: Are Anti-Factor B Autoantibodies the Answer?

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2020-03-06       Impact factor: 10.121

5.  Clusters Not Classifications: Making Sense of Complement-Mediated Kidney Injury.

Authors:  H Terence Cook; Matthew C Pickering
Journal:  J Am Soc Nephrol       Date:  2017-12-11       Impact factor: 10.121

Review 6.  [Membranoproliferative glomerulonephritis and C3 glomerulopathy].

Authors:  B Hohenstein; K Amann; J Menne
Journal:  Internist (Berl)       Date:  2019-05       Impact factor: 0.743

7.  Archetype Analysis Identifies Distinct Profiles in Renal Transplant Recipients with Transplant Glomerulopathy Associated with Allograft Survival.

Authors:  Olivier Aubert; Sarah Higgins; Yassine Bouatou; Daniel Yoo; Marc Raynaud; Denis Viglietti; Marion Rabant; Luis Hidalgo; Denis Glotz; Christophe Legendre; Michel Delahousse; Nikhil Shah; Banu Sis; Patricia Campbell; Michael Mengel; Xavier Jouven; Jean-Paul Duong Van Huyen; Carmen Lefaucheur; Alexandre Loupy
Journal:  J Am Soc Nephrol       Date:  2019-03-14       Impact factor: 10.121

Review 8.  A clinical approach to children with C3 glomerulopathy.

Authors:  Marina Vivarelli; Nicole van de Kar; Raffaella Labbadia; Francesca Diomedi-Camassei; Joshua M Thurman
Journal:  Pediatr Nephrol       Date:  2021-05-18       Impact factor: 3.714

9.  Mycophenolate Mofetil in C3 Glomerulopathy and Pathogenic Drivers of the Disease.

Authors:  Fernando Caravaca-Fontán; Montserrat M Díaz-Encarnación; Laura Lucientes; Teresa Cavero; Virginia Cabello; Gema Ariceta; Luis F Quintana; Helena Marco; Xoana Barros; Natalia Ramos; Nuria Rodríguez-Mendiola; Sonia Cruz; Gema Fernández-Juárez; Adela Rodríguez; Ana Pérez de José; Cristina Rabasco; Raquel Rodado; Loreto Fernández; Vanessa Pérez Gómez; Ana I Ávila; Luis Bravo; Javier Lumbreras; Natalia Allende; Maria Dolores Sanchez de la Nieta; Eva Rodríguez; Teresa Olea; Marta Melgosa; Ana Huerta; Rosa Miquel; Carmen Mon; Gloria Fraga; Alberto de Lorenzo; Juliana Draibe; Marta Cano-Megías; Fayna González; Amir Shabaka; Maria Esperanza López-Rubio; María Ángeles Fenollosa; Luis Martín-Penagos; Iara Da Silva; Juana Alonso Titos; Santiago Rodríguez de Córdoba; Elena Goicoechea de Jorge; Manuel Praga
Journal:  Clin J Am Soc Nephrol       Date:  2020-08-19       Impact factor: 8.237

10.  Deep learning-based framework for the distinction of membranous nephropathy: a new approach through hyperspectral imagery.

Authors:  Tianqi Tu; Xueling Wei; Yue Yang; Nianrong Zhang; Wei Li; Xiaowen Tu; Wenge Li
Journal:  BMC Nephrol       Date:  2021-06-19       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.